2025 Diabetes Labelling 
Express Pharma
APRIL 8, 2025
Novo Nordisk has released full results from the SOUL cardiovascular outcomes trial, a phase 3b study evaluating the impact of oral semaglutide on adults with type 2 diabetes who also have cardiovascular disease (CVD) and/or chronic kidney disease (CKD). Notably, participants from the Asian region showed a 27 per cent reduction in MACE risk.
Express Pharma
DECEMBER 2, 2024
The company’s Phase III product Rybelsus, already FDA approved for cardiovascular risk factors and type 2 diabetes, is being positioned for a label expansion to include obesity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 7, 2023
The recent rallying of Lilly’s market value has come as the result of two major announcements: its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completed its second final-stage trial for obesity, and its experimental treatment for Alzheimer’s disease completed its Phase III trial.
European Pharmaceutical Review
MARCH 14, 2024
This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). The safety profile in the open-label extension was consistent with the randomised period and with the overall population of patients with IgAN.
European Pharmaceutical Review
MARCH 14, 2024
This month, new data from Novo Nordisk has revealed that semaglutide could become the first GLP-1 treatment option for patients with type 2 diabetes and chronic kidney disease (CKD). The safety profile in the open-label extension was consistent with the randomised period and with the overall population of patients with IgAN.
Quality Matters
SEPTEMBER 9, 2024
The area is populated with apps and other software designed to treat various ailments including mental health disorders, diabetes, asthma, insomnia, substance-use disorders, and beyond. In the meantime, USP encourages interested parties to apply to become involved in developing DTx standards as a USP Expert Volunteer in the 2025-2030 cycle.
PharmaShots
MAY 3, 2023
Eli Lilly Launches Rezvoglar as Second Interchangeable Insulin Biosimilar in the US Date- April 01, 2023 Product: Rezvoglar The company launched Rezvoglar, a second interchangeable biosimilar insulin product to Lantus (insulin glargine) in the US market for the treatment of patients with diabetes. Infections were observed in 33.9%
Expert insights. Personalized for you.
89 
Let's personalize your content